FIELD: medicine, medicinal virology. SUBSTANCE: immunization is carried out with vaccine containing at least two strains of influenza virus type B and/or each of influenza virus subtype A. Vaccine concentration is at the range from 2.7-4.2 mcg/0.5 ml to 2.7-4.2 ng/0.5 ml hemagglutinin for inactivated vaccine and from 3 x 4.5 lg ID50/0.2 ml - 3 x 6.5 lg ID50/0.2 ml to 3 x 3.5 lg ID50/0.2 ml - 3 x 5.5 lg ID50/0.2 ml for live antiinfluenza vaccine. Immunization requires the corresponding vaccine involving polyvalent preparation with that strain composition. EFFECT: enhanced effectiveness and safety of vaccine prophylaxis. 2 cl, 9 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING TETRAVALENT SUBUNIT INFLUENZA VACCINE | 2019 |
|
RU2740751C1 |
| METHOD FOR ASSESSING THE REPRODUCTIVE ACTIVITY OF INFLUENZA VIRUSES IN A TRIVALENT AND QUADRIVALENT LIVE INFLUENZA VACCINE | 2019 |
|
RU2735293C1 |
| METHOD FOR OBTAINING A TETRAVALENT VACCINE FOR THE PREVENTION OF INFLUENZA | 2020 |
|
RU2754398C1 |
| PENTAVALENT SUBUNIT VACCINE AGAINST RESPIRATORY INFECTIONS AND METHOD OF ITS PREPARATION | 2022 |
|
RU2804948C2 |
| INFLUENZA VIRUS STRAIN A/Hongkong/1/68/162/35 (H3N2) - UNIVERSAL DONOR OF INTERNAL GENES FOR REASSORTANTS, AND REASSORTANT STRAINS A/SPB/GK/09 (H1N1) AND A/HK/Astana/6:2/2010 (H5N1) PREPARED THEREOF | 2011 |
|
RU2511431C2 |
| INFLUENZA VIRUS STRAIN INFLUBACT-H7/PSPA FOR THE PRODUCTION OF A COMBINED VACCINE AGAINST INFLUENZA A VIRUS AND BACTERIAL PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE | 2021 |
|
RU2776196C1 |
| METHOD FOR INCREASING ANTITUMOUR RESISTANCE, ANTIOXIDANT AND IMMUNOSTIMULATING EFFECTS ON THE BODY | 2019 |
|
RU2755638C2 |
| INFLUENZA VACCINE AND METHOD FOR PREPARING IT | 2010 |
|
RU2446824C2 |
| METHOD OF PRODUCTION OF LIVE CULTURE INFLUENZA VIRUS VACCINES | 2003 |
|
RU2330885C2 |
| STRAIN OF AVIAN INFLUENZA A VIRUS (H5N2) GKV N 2340 FOR INFLUENZA INFECTION MODELLING | 1999 |
|
RU2163637C1 |
